| Maureen Chapman, CNM, APRN | |
|
1835 N Paris Ave, Port Royal, SC 29935-2029 | |
| (843) 524-8151 | |
| (843) 524-1954 |
| Full Name | Maureen Chapman |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 1835 N Paris Ave, Port Royal, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043688989 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 3384 (South Carolina) | Primary |
| 367A00000X | Advanced Practice Midwife | MW008326L (Pennsylvania) | Secondary |
| Entity Name | Beaufort County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457922007 PECOS PAC ID: 7810809365 Enrollment ID: O20050208000354 |
News Archive
Massachusetts officials are reviving the state's ambitious plan to change how doctors and hospitals are paid, aiming to hand the Legislature a specific proposal by Jan. 1 to end disagreement over controlling health spending.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.
STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive refractive lenses that go inside the eye, today announced the completion of the first procedures to implant its recently CE Mark-approved Visian Implantable Collamer Lens V4c design.
Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013.
The Foundation for Innovative New Diagnostics and Unitaid announced today that the organizations have launched a call for expressions of interest to accelerate the availability and manufacturing scale-up of rapid diagnostic tests for the detection of SARS-CoV-2 antigens. Reliable, affordable Ag RDTs have been identified as key tools in the global response to COVID-19, as they could enable robust detection of active SARS-CoV-2 infection for both patient management and contact tracing purposes in decentralized settings.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maureen Chapman, CNM, APRN 1835 N Paris Ave, Port Royal, SC 29935-2029 Ph: (843) 524-8151 | Maureen Chapman, CNM, APRN 1835 N Paris Ave, Port Royal, SC 29935-2029 Ph: (843) 524-8151 |
News Archive
Massachusetts officials are reviving the state's ambitious plan to change how doctors and hospitals are paid, aiming to hand the Legislature a specific proposal by Jan. 1 to end disagreement over controlling health spending.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.
STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive refractive lenses that go inside the eye, today announced the completion of the first procedures to implant its recently CE Mark-approved Visian Implantable Collamer Lens V4c design.
Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013.
The Foundation for Innovative New Diagnostics and Unitaid announced today that the organizations have launched a call for expressions of interest to accelerate the availability and manufacturing scale-up of rapid diagnostic tests for the detection of SARS-CoV-2 antigens. Reliable, affordable Ag RDTs have been identified as key tools in the global response to COVID-19, as they could enable robust detection of active SARS-CoV-2 infection for both patient management and contact tracing purposes in decentralized settings.
› Verified 1 days ago